Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fanpu Ji

Showing results (131-140 of 146) with videos related to

Pageof 15
Sort By:
Journal of Hepatology|November 17, 2021
Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysisXinxing Tantai, Yi Liu, Yee Hui Yeo, et al.
The Lancet. Gastroenterology & Hepatology|March 24, 2019
Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysisJie Li, Biyao Zou, Yee Hui Yeo, et al.
Journal of Gastroenterology and Hepatology|August 26, 2020
High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3bFanpu Ji, Jie Li, Li Liu, et al.
Journal of Hepatology|May 17, 2019
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysisFanpu Ji, Yee Hui Yeo, Mike Tzuhen Wei, et al.
Therapeutic Advances in Gastroenterology|May 23, 2022
Practice guidance for the use of terlipressin for liver cirrhosis-related complicationsXingshun Qi, Zhaohui Bai, Qiang Zhu, et al.
Alimentary Pharmacology & Therapeutics|March 31, 2026
Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma (CHANCE2311)Rong Ding, Jin-Feng Bai, Zhi-Cheng Jin, et al.
Eclinicalmedicine|February 18, 2026
Transarterial chemoembolization (TACE) combined with immunotherapy and anti-angiogenic agents in intermediate-stage hepatocellular carcinoma (CHANCE2202): a target trial emulation studyJian-Jian Chen, Zhi-Cheng Jin, Jia-Wei Zhou, et al.
Journal of Cachexia, Sarcopenia and Muscle|November 27, 2024
Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213)Zhi-Cheng Jin, Jia-Wei Zhou, Jian-Jian Chen, et al.
Medcomm|November 27, 2025
Variations in Estimated Glomerular Filtration Rate Across Countries in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Their Association With Liver Fibrosis: A Multicenter StudyJing Zhao, Ferenc E Mózes, Xin-Yu Xu, et al.
Hepatology (Baltimore, Md.)|December 7, 2024
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapyBernhard Scheiner, Beodeul Kang, Lorenz Balcar, et al.
Pageof 15

Showing results (131-140 of 146) with videos related to

Sort By:
Pageof 15
Journal of Hepatology|November 17, 2021
Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysisXinxing Tantai, Yi Liu, Yee Hui Yeo, et al.
The Lancet. Gastroenterology & Hepatology|March 24, 2019
Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysisJie Li, Biyao Zou, Yee Hui Yeo, et al.
Journal of Gastroenterology and Hepatology|August 26, 2020
High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3bFanpu Ji, Jie Li, Li Liu, et al.
Journal of Hepatology|May 17, 2019
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysisFanpu Ji, Yee Hui Yeo, Mike Tzuhen Wei, et al.
Therapeutic Advances in Gastroenterology|May 23, 2022
Practice guidance for the use of terlipressin for liver cirrhosis-related complicationsXingshun Qi, Zhaohui Bai, Qiang Zhu, et al.
Alimentary Pharmacology & Therapeutics|March 31, 2026
Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma (CHANCE2311)Rong Ding, Jin-Feng Bai, Zhi-Cheng Jin, et al.
Eclinicalmedicine|February 18, 2026
Transarterial chemoembolization (TACE) combined with immunotherapy and anti-angiogenic agents in intermediate-stage hepatocellular carcinoma (CHANCE2202): a target trial emulation studyJian-Jian Chen, Zhi-Cheng Jin, Jia-Wei Zhou, et al.
Journal of Cachexia, Sarcopenia and Muscle|November 27, 2024
Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213)Zhi-Cheng Jin, Jia-Wei Zhou, Jian-Jian Chen, et al.
Medcomm|November 27, 2025
Variations in Estimated Glomerular Filtration Rate Across Countries in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Their Association With Liver Fibrosis: A Multicenter StudyJing Zhao, Ferenc E Mózes, Xin-Yu Xu, et al.
Hepatology (Baltimore, Md.)|December 7, 2024
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapyBernhard Scheiner, Beodeul Kang, Lorenz Balcar, et al.
Pageof 15